{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-338318","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2025-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.369284+00:00","generated_at":"2026-05-16T11:54:46.348623+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Climb Bio sues Alumis to avoid $3M milestone payment, disputes 'Product' definition under APA","bullets":["Filed complaint in Delaware Superior Court seeking declaratory judgment that budoprutug is not a 'Product' under the APA.","Alumis invoiced $3M milestone payment due Jan 1, 2026 for Phase 2 initiation; Climb denies any obligation.","Climb dosed first patient in Phase 2 trial on Nov 17, 2025; claims no Royalty-Bearing Patents exist to trigger milestone.","Dispute centers on interpretation of APA; Climb argues no patents transferred or filed within nine months of closing.","Climb states it attempted to resolve out of court but Alumis refused."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-338318","json":"https://secwatch.observer/filing/0001193125-25-338318.json","markdown":"https://secwatch.observer/filing/0001193125-25-338318.md","text":"https://secwatch.observer/filing/0001193125-25-338318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525338318/0001193125-25-338318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525338318/d19559d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:54:46.348623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}